Cargando…

Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation

The aim of this study was to enhance the solubility of rosuvastatin (RST) calcium by developing β-cyclodextrin-g-poly(2-acrylamido-2-methylpropane sulfonic acid [AMPS]) hydrogel microparticles through aqueous free-radical polymerization technique. Prepared hydrogel microparticles were characterized...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarfraz, Rai Muhammad, Ahmad, Mahmood, Mahmood, Asif, Akram, Muhammad Rouf, Abrar, Asad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661467/
https://www.ncbi.nlm.nih.gov/pubmed/29123380
http://dx.doi.org/10.2147/DDDT.S143712
_version_ 1783274485420392448
author Sarfraz, Rai Muhammad
Ahmad, Mahmood
Mahmood, Asif
Akram, Muhammad Rouf
Abrar, Asad
author_facet Sarfraz, Rai Muhammad
Ahmad, Mahmood
Mahmood, Asif
Akram, Muhammad Rouf
Abrar, Asad
author_sort Sarfraz, Rai Muhammad
collection PubMed
description The aim of this study was to enhance the solubility of rosuvastatin (RST) calcium by developing β-cyclodextrin-g-poly(2-acrylamido-2-methylpropane sulfonic acid [AMPS]) hydrogel microparticles through aqueous free-radical polymerization technique. Prepared hydrogel microparticles were characterized for percent entrapment efficiency, solubility studies, Fourier transform infrared spectroscopy, differential scanning calorimetry, thermal gravimetric analysis, powder X-ray diffraction, scanning electron microscopy, zeta size and potential, swelling and release studies. Formulations (HS1–HS9) have shown entrapment efficiency between 83.50%±0.30% and 88.50%±0.25%, and optimum release was offered by formulation HS7 at both pH levels, ie, 1.2 (89%) and 7.4 (92%). The majority of microparticles had a particle size of less than 500 µm and zeta potential of −37 mV. Similarly, optimum solubility, ie, 10.66-fold, was determined at pH 6.8 as compared to pure RST calcium, ie, 7.30-fold. In vivo studies on fabricated hydrogel microparticulate system in comparison to pure drug were carried out, and better results regarding pharmacokinetic parameters were seen in the case of hydrogel microparticles. A potential approach for solubility enhancement of RST calcium and other hydrophobic moieties was successfully developed.
format Online
Article
Text
id pubmed-5661467
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56614672017-11-09 Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation Sarfraz, Rai Muhammad Ahmad, Mahmood Mahmood, Asif Akram, Muhammad Rouf Abrar, Asad Drug Des Devel Ther Original Research The aim of this study was to enhance the solubility of rosuvastatin (RST) calcium by developing β-cyclodextrin-g-poly(2-acrylamido-2-methylpropane sulfonic acid [AMPS]) hydrogel microparticles through aqueous free-radical polymerization technique. Prepared hydrogel microparticles were characterized for percent entrapment efficiency, solubility studies, Fourier transform infrared spectroscopy, differential scanning calorimetry, thermal gravimetric analysis, powder X-ray diffraction, scanning electron microscopy, zeta size and potential, swelling and release studies. Formulations (HS1–HS9) have shown entrapment efficiency between 83.50%±0.30% and 88.50%±0.25%, and optimum release was offered by formulation HS7 at both pH levels, ie, 1.2 (89%) and 7.4 (92%). The majority of microparticles had a particle size of less than 500 µm and zeta potential of −37 mV. Similarly, optimum solubility, ie, 10.66-fold, was determined at pH 6.8 as compared to pure RST calcium, ie, 7.30-fold. In vivo studies on fabricated hydrogel microparticulate system in comparison to pure drug were carried out, and better results regarding pharmacokinetic parameters were seen in the case of hydrogel microparticles. A potential approach for solubility enhancement of RST calcium and other hydrophobic moieties was successfully developed. Dove Medical Press 2017-10-24 /pmc/articles/PMC5661467/ /pubmed/29123380 http://dx.doi.org/10.2147/DDDT.S143712 Text en © 2017 Sarfraz et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Sarfraz, Rai Muhammad
Ahmad, Mahmood
Mahmood, Asif
Akram, Muhammad Rouf
Abrar, Asad
Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation
title Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation
title_full Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation
title_fullStr Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation
title_full_unstemmed Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation
title_short Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation
title_sort development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661467/
https://www.ncbi.nlm.nih.gov/pubmed/29123380
http://dx.doi.org/10.2147/DDDT.S143712
work_keys_str_mv AT sarfrazraimuhammad developmentofbcyclodextrinbasedhydrogelmicroparticlesforsolubilityenhancementofrosuvastatinaninvitroandinvivoevaluation
AT ahmadmahmood developmentofbcyclodextrinbasedhydrogelmicroparticlesforsolubilityenhancementofrosuvastatinaninvitroandinvivoevaluation
AT mahmoodasif developmentofbcyclodextrinbasedhydrogelmicroparticlesforsolubilityenhancementofrosuvastatinaninvitroandinvivoevaluation
AT akrammuhammadrouf developmentofbcyclodextrinbasedhydrogelmicroparticlesforsolubilityenhancementofrosuvastatinaninvitroandinvivoevaluation
AT abrarasad developmentofbcyclodextrinbasedhydrogelmicroparticlesforsolubilityenhancementofrosuvastatinaninvitroandinvivoevaluation